The decline in antibodies to hepatitis C virus during antiviral therapy

The goal of the study was to analyze B-cell response to hepatitis C virus during antiviral therapy among responders and non-responders. The content of antibodies to individual structural and non-structural HCV proteins was investigated during two years in three groups of patients: initial responders...

Full description

Saved in:
Bibliographic Details
Published in:Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry Biomedical chemistry, 2009-06, Vol.3 (2), p.202-209
Main Authors: Nikolaeva, L. I., Makashova, V. V., Petrova, E. V., Shipulin, G. A., Samokhvalov, E. I., Tokmalaev, A. K., Lvov, D. K.
Format: Article
Language:English
Subjects:
Antiviral drugs
Biochemistry
Bioorganic Chemistry
Chemistry
Chemistry and Materials Science
Clinical Studies
Hepatitis
Hepatitis C virus
Medicinal Chemistry
Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The goal of the study was to analyze B-cell response to hepatitis C virus during antiviral therapy among responders and non-responders. The content of antibodies to individual structural and non-structural HCV proteins was investigated during two years in three groups of patients: initial responders, non-responders and a reference group (without therapy). Treated patients in all groups exhibited the decrease in antibodies to analyzed HCV proteins, but with different patterns. The first statistically significant differences in the decline of the virus-specific antibodies between initial responders and non-responders were observed within the first three months after the beginning of therapy. Some treated patients demonstrated the decrease in antibody levels to HCV proteins after the end of therapy.
ISSN:1990-7508
1990-7516
DOI:10.1134/S1990750809020127